Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 7664265.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Elevated dihydrotestosterone levels have been suggested to increase the risk of prostate cancer. The human SRD5A2 gene encodes the type II steroid 5 alpha-reductase, which converts testosterone to the more bioactive compound dihydrotestosterone. We have determined the distribution of a dinucleotide repeat in low-risk Asian-Americans, high-risk African-Americans, and intermediate-risk non-Hispanic Whites. We found this marker to be more polymorphic than previously reported, with some alleles being specific to African-Americans. Genetic variants of the SRD5A2 gene may play a role in predisposition to prostate cancer and in explaining the substantial racial/ethnic variability in risk.
Medical subject headings
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
- Prostatic Neoplasms